Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Forums: Virtual Conferences
Sixth International Conference on Alzheimer’s Disease and Related Disorders: News
Conference Index | Round Tables | Selected Abstracts | News Summaries

Fibril-busting Mystery Herb
by Brian J. Cummings

22 July 1998. While a number of drug companies have been pumping big bucks into creating novel molecules capable of inhibiting formation of A-beta fibrils, along comes Alan Snow and his colleagues at the University of Washington and his Seattle-based company, ProteoTech, Inc., with a commercially available "plant extract" that appears to do the trick (abstract 1070). This substance can apparently dissolve pre-exisiting amyloid fibrils in an in vitro Thioflavin T fluorometry assay. Snow presented data that this compound can "dissolve" both Abeta1-42 fibrils and islet amyloid fibrils.

Snow indicated that this substance was discovered by screening off-the-shelf health food supplements and finding one that yielded positive results in the Thioflavin assay. He also stated that this food supplement is readily available and produced by several different manufactures, although he declined to identify the compound. In response to the question about adsorption in the gut and whether this compound can cross the blood brain barrier, Snow said that those tests have not been run. He added that the extract is a low molecular weight lipophilic compound, so he has hopes that it will get into the brain.

Snow's company is currently negotiating with a major supplier of the extract to run a human clinical trial, although it might be more appropriate to first test the compound in a transgenic mouse. Snow said such tests have not yet been done, and he would be interested in such a study. Got mice? Give him a call. I'll hold off on buying stock until data shows that compound X can cross the blood brain barrier in sufficient quantities to actually reduce Abeta plaques in a transgenic animal.




Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad